Your browser is no longer supported. Please, upgrade your browser.
RETA Reata Pharmaceuticals, Inc. daily Stock Chart
Reata Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-10.73 Insider Own0.10% Shs Outstand33.27M Perf Week2.46%
Market Cap3.67B Forward P/E- EPS next Y-10.51 Insider Trans3.18% Shs Float27.10M Perf Month7.19%
Income-343.20M PEG- EPS next Q-1.98 Inst Own82.10% Short Float13.07% Perf Quarter-29.01%
Sales15.30M P/S239.81 EPS this Y-228.10% Inst Trans-0.04% Short Ratio10.57 Perf Half Y-23.64%
Book/sh6.96 P/B16.25 EPS next Y-34.10% ROA-60.80% Target Price- Perf Year-38.85%
Cash/sh18.81 P/C6.01 EPS next 5Y- ROE-211.30% 52W Range88.17 - 257.96 Perf YTD-44.69%
Dividend- P/FCF- EPS past 5Y- ROI-45.40% 52W High-56.17% Beta1.64
Dividend %- Quick Ratio13.60 Sales past 5Y-12.60% Gross Margin- 52W Low28.24% ATR4.99
Employees220 Current Ratio13.60 Sales Q/Q-60.30% Oper. Margin- RSI (14)60.10 Volatility4.28% 5.17%
OptionableYes Debt/Eq0.30 EPS Q/Q-77.70% Profit Margin- Rel Volume0.49 Prev Close112.78
ShortableYes LT Debt/Eq0.30 EarningsAug 10 BMO Payout- Avg Volume334.97K Price113.07
Recom1.10 SMA206.98% SMA507.27% SMA200-26.20% Volume165,022 Change0.26%
Jul-10-20Resumed Stifel Buy $315 → $280
Jun-17-20Initiated BTIG Research Buy $237
Nov-13-19Downgrade National Securities Buy → Neutral
Sep-26-19Initiated National Securities Buy $130
Sep-25-18Reiterated Leerink Partners Outperform $116 → $139
Sep-13-17Initiated Leerink Partners Outperform $43
Jul-25-17Reiterated Citigroup Buy $39 → $87
Apr-13-17Initiated Ladenburg Thalmann Buy $55
Feb-23-17Initiated Stifel Buy $38
Jan-25-17Initiated Robert W. Baird Outperform $43
Jun-20-16Initiated Piper Jaffray Overweight $33
Jun-20-16Initiated Citigroup Buy
Oct-19-20 05:08PM  
Oct-18-20 10:45PM  
Oct-17-20 04:06PM  
Oct-16-20 08:00PM  
Oct-15-20 11:19PM  
Sep-16-20 11:26AM  
Sep-14-20 09:50AM  
Sep-09-20 11:30AM  
Sep-03-20 06:45AM  
Aug-14-20 09:22AM  
Aug-12-20 11:10PM  
Aug-11-20 11:41AM  
Aug-10-20 07:31PM  
Aug-03-20 06:45AM  
Jul-30-20 04:05PM  
Jul-28-20 06:45AM  
Jul-13-20 05:02PM  
Jul-07-20 06:45AM  
Jul-03-20 04:53PM  
Jun-30-20 02:40PM  
Jun-24-20 10:10AM  
Jun-19-20 08:43AM  
Jun-18-20 09:42AM  
Jun-12-20 06:31PM  
Jun-11-20 07:30AM  
Jun-10-20 11:30AM  
Jun-03-20 12:55PM  
May-12-20 03:00PM  
May-11-20 06:45PM  
May-04-20 04:35PM  
Apr-13-20 01:06PM  
Apr-07-20 09:50AM  
Mar-31-20 04:28PM  
Mar-30-20 04:05PM  
Mar-22-20 08:30PM  
Mar-20-20 11:30AM  
Feb-27-20 03:09AM  
Feb-19-20 04:01PM  
Feb-12-20 04:01PM  
Feb-04-20 11:28AM  
Jan-31-20 04:41PM  
Jan-17-20 05:40PM  
Dec-15-19 05:59AM  
Dec-09-19 09:52AM  
Dec-04-19 08:20PM  
Nov-25-19 03:00PM  
Nov-18-19 11:15AM  
Nov-15-19 12:54PM  
Nov-13-19 07:15PM  
Nov-12-19 04:01PM  
Nov-11-19 05:15PM  
Nov-05-19 06:45AM  
Oct-30-19 10:33AM  
Oct-29-19 01:37PM  
Oct-20-19 08:08AM  
Oct-17-19 08:58AM  
Oct-16-19 07:06AM  
Oct-15-19 05:13PM  
Oct-14-19 04:36PM  
Oct-11-19 10:00AM  
Oct-10-19 04:18PM  
Oct-01-19 07:22AM  
Sep-11-19 10:02AM  
Sep-06-19 09:40AM  
Sep-02-19 03:09PM  
Aug-29-19 07:38AM  
Aug-28-19 04:01PM  
Aug-12-19 01:47AM  
Aug-08-19 07:55AM  
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease(CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct phase 2 study for various form of CKD, such as IgA nephropathy, type 1 diabetic, and focal segmental glomerulosclerosis. It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of neurological diseases, such as diabetic neuropathy; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), as well as initiated phase 3 Falcon trial for the treatment of ADPKD. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Plano, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Soni Manmeet SinghCOO and CFOAug 14Buy100.213,000300,6303,000Aug 14 03:45 PM
Castellanos ElaineVP, Chief Accounting OfficerJun 01Sale143.972,000287,94015,146Jun 01 05:27 PM
Castellanos ElaineVP, Chief Accounting OfficerMar 02Sale194.322,000388,64015,146Mar 02 03:02 PM
Wilson Jason DouglasExecutive VP of OperationsDec 16Sale203.2610,0002,032,59112,950Dec 17 05:30 PM
Castellanos ElaineVP, Chief Accounting OfficerDec 02Sale194.242,000388,48015,146Dec 03 04:03 PM
ROSE WILLIAMMember of 10% owner groupNov 20Sale212.536,5911,400,77119,795Dec 05 05:22 PM
ROSE WILLIAMMember of 10% owner groupNov 19Sale210.002,000420,00026,386Dec 05 05:22 PM
Traweek James W JR10% OwnerNov 18Buy183.0040,2187,359,8943,063,567Nov 18 05:23 PM
McGaughy R Kent JrDirectorNov 18Buy183.0040,2187,359,8943,063,567Nov 18 05:21 PM
CPMG IncDirectorNov 18Buy183.0040,2187,359,894282,246Nov 18 05:20 PM
ROSE WILLIAMMember of 10% owner groupNov 18Sale202.041,000202,04028,386Dec 05 05:22 PM
Castellanos ElaineVP, Chief Accounting OfficerOct 28Sale200.004,000800,00015,146Oct 30 11:32 AM
Castellanos ElaineVP, Chief Accounting OfficerOct 25Sale190.002,000380,00015,146Oct 28 04:41 PM